Literature DB >> 21708117

Expression of endoplasmic reticulum stress proteins is a candidate marker of brain metastasis in both ErbB-2+ and ErbB-2- primary breast tumors.

Rebeca Sanz-Pamplona1, Ramón Aragüés, Keltouma Driouch, Berta Martín, Baldo Oliva, Miguel Gil, Susana Boluda, Pedro L Fernández, Antonio Martínez, Víctor Moreno, Juan J Acebes, Rosette Lidereau, Fabien Reyal, Marc J Van de Vijver, Angels Sierra.   

Abstract

The increasing incidence of breast cancer brain metastasis in patients with otherwise well-controlled systemic cancer is a key challenge in cancer research. It is necessary to understand the properties of brain-tropic tumor cells to identify patients at risk for brain metastasis. Here we attempt to identify functional phenotypes that might enhance brain metastasis. To obtain an accurate classification of brain metastasis proteins, we mapped organ-specific brain metastasis gene expression signatures onto an experimental protein-protein interaction network based on brain metastatic cells. Thirty-seven proteins were differentially expressed between brain metastases and non-brain metastases. Analysis of metastatic tissues, the use of bioinformatic approaches, and the characterization of protein expression in tumors with or without metastasis identified candidate markers. A multivariate analysis based on stepwise logistic regression revealed GRP94, FN14, and inhibin as the best combination to discriminate between brain and non-brain metastases (ROC AUC = 0.85, 95% CI = 0.73 to 0.96 for the combination of the three proteins). These markers substantially improve the discrimination of brain metastasis compared with ErbB-2 alone (AUC = 0.76, 95% CI = 0.60 to 0.93). Furthermore, GRP94 was a better negative marker (LR = 0.16) than ErbB-2 (LR = 0.42). We conclude that, in breast carcinomas, certain proteins associated with the endoplasmic reticulum stress phenotype are candidate markers of brain metastasis.
Copyright © 2011 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21708117      PMCID: PMC3157240          DOI: 10.1016/j.ajpath.2011.04.037

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  49 in total

1.  The tumor necrosis factor-like weak inducer of apoptosis (TWEAK)-fibroblast growth factor-inducible 14 (Fn14) signaling system regulates glioma cell survival via NFkappaB pathway activation and BCL-XL/BCL-W expression.

Authors:  Nhan L Tran; Wendy S McDonough; Benjamin A Savitch; Thomas F Sawyer; Jeffrey A Winkles; Michael E Berens
Journal:  J Biol Chem       Date:  2004-12-16       Impact factor: 5.157

2.  PIANA: protein interactions and network analysis.

Authors:  Ramon Aragues; Daniel Jaeggi; Baldo Oliva
Journal:  Bioinformatics       Date:  2006-03-01       Impact factor: 6.937

3.  Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer.

Authors:  Yixin Wang; Jan G M Klijn; Yi Zhang; Anieta M Sieuwerts; Maxime P Look; Fei Yang; Dmitri Talantov; Mieke Timmermans; Marion E Meijer-van Gelder; Jack Yu; Tim Jatkoe; Els M J J Berns; David Atkins; John A Foekens
Journal:  Lancet       Date:  2005 Feb 19-25       Impact factor: 79.321

4.  Genes that mediate breast cancer metastasis to lung.

Authors:  Andy J Minn; Gaorav P Gupta; Peter M Siegel; Paula D Bos; Weiping Shu; Dilip D Giri; Agnes Viale; Adam B Olshen; William L Gerald; Joan Massagué
Journal:  Nature       Date:  2005-07-28       Impact factor: 49.962

Review 5.  Pathobiology of brain metastases.

Authors:  N Nathoo; A Chahlavi; G H Barnett; S A Toms
Journal:  J Clin Pathol       Date:  2005-03       Impact factor: 3.411

Review 6.  Therapeutic management of brain metastasis.

Authors:  Evert C A Kaal; Charles G J H Niël; Charles J Vecht
Journal:  Lancet Neurol       Date:  2005-05       Impact factor: 44.182

Review 7.  Breast cancer metastasis to the central nervous system.

Authors:  Robert J Weil; Diane C Palmieri; Julie L Bronder; Andreas M Stark; Patricia S Steeg
Journal:  Am J Pathol       Date:  2005-10       Impact factor: 4.307

8.  Central nervous system metastases in women after multimodality therapy for high risk breast cancer.

Authors:  Lisa A Carey; Matthew G Ewend; Richard Metzger; Lynda Sawyer; E Claire Dees; Carolyn I Sartor; Dominic T Moore; Mark L Graham
Journal:  Breast Cancer Res Treat       Date:  2004-12       Impact factor: 4.872

9.  Risk factors for brain relapse in patients with metastatic breast cancer.

Authors:  K Slimane; F Andre; S Delaloge; A Dunant; A Perez; J Grenier; C Massard; M Spielmann
Journal:  Ann Oncol       Date:  2004-11       Impact factor: 32.976

10.  Organ-selective chemoresistance in metastasis from human breast cancer cells: inhibition of apoptosis, genetic variability and microenvironment at the metastatic focus.

Authors:  Bin Gu; Laura España; Olga Méndez; Angels Torregrosa; Angels Sierra
Journal:  Carcinogenesis       Date:  2004-09-03       Impact factor: 4.944

View more
  21 in total

Review 1.  Tools for protein-protein interaction network analysis in cancer research.

Authors:  Rebeca Sanz-Pamplona; Antoni Berenguer; Xavier Sole; David Cordero; Marta Crous-Bou; Jordi Serra-Musach; Elisabet Guinó; Miguel Ángel Pujana; Víctor Moreno
Journal:  Clin Transl Oncol       Date:  2012-01       Impact factor: 3.405

2.  Crucial microRNAs and genes of human primary breast cancer explored by microRNA-mRNA integrated analysis.

Authors:  Yang Yang; Yiqiao Xing; Chaoqun Liang; Liya Hu; Fei Xu; Yuan Chen
Journal:  Tumour Biol       Date:  2015-02-14

3.  Fn14 receptor promotes invasive potential and metastatic capacity of non-small lung adenocarcinoma cells through the up-regulation of integrin α6.

Authors:  J Jandova; C J Mason; S C Pawar; G S Watts
Journal:  Neoplasma       Date:  2015       Impact factor: 2.575

Review 4.  A methodological approach to unravel organ-specific breast cancer metastasis.

Authors:  Sébastien Nola; Soraya Sin; Florian Bonin; Rosette Lidereau; Keltouma Driouch
Journal:  J Mammary Gland Biol Neoplasia       Date:  2012-05-25       Impact factor: 2.673

Review 5.  Intrinsic cancer subtypes--next steps into personalized medicine.

Authors:  Cristina Santos; Rebeca Sanz-Pamplona; Ernest Nadal; Julieta Grasselli; Sonia Pernas; Rodrigo Dienstmann; Victor Moreno; Josep Tabernero; Ramon Salazar
Journal:  Cell Oncol (Dordr)       Date:  2015-01-14       Impact factor: 6.730

6.  Endoplasmic Reticulum-resident Heat Shock Protein 90 (HSP90) Isoform Glucose-regulated Protein 94 (GRP94) Regulates Cell Polarity and Cancer Cell Migration by Affecting Intracellular Transport.

Authors:  Suman Ghosh; Heather E Shinogle; Nadezhda A Galeva; Rick T Dobrowsky; Brian S J Blagg
Journal:  J Biol Chem       Date:  2016-02-12       Impact factor: 5.157

7.  FN14 expression correlates with MET in NSCLC and promotes MET-driven cell invasion.

Authors:  Timothy G Whitsett; Shannon P Fortin Ensign; Harshil D Dhruv; Landon J Inge; Paul Kurywchak; Kerri K Wolf; Janine LoBello; Christopher B Kingsley; Jeffrey W Allen; Glen J Weiss; Nhan L Tran
Journal:  Clin Exp Metastasis       Date:  2014-04-08       Impact factor: 5.150

8.  GRP94 promotes brain metastasis by engaging pro-survival autophagy.

Authors:  Naiara Santana-Codina; Laia Muixí; Ruben Foj; Rebeca Sanz-Pamplona; Miriam Badia-Villanueva; Agata Abramowicz; Anna Marcé-Grau; Ana María Cosialls; Joan Gil; Ivan Archilla; Leire Pedrosa; Josep Gonzalez; Iban Aldecoa; Angels Sierra
Journal:  Neuro Oncol       Date:  2020-05-15       Impact factor: 12.300

9.  OSU-03012 sensitizes breast cancers to lapatinib-induced cell killing: a role for Nck1 but not Nck2.

Authors:  N Winston West; Aileen Garcia-Vargas; Charles E Chalfant; Margaret A Park
Journal:  BMC Cancer       Date:  2013-05-24       Impact factor: 4.430

Review 10.  Breast cancer brain metastases: a review of the literature and a current multidisciplinary management guideline.

Authors:  M J Gil-Gil; M Martinez-Garcia; A Sierra; G Conesa; S Del Barco; S González-Jimenez; S Villà
Journal:  Clin Transl Oncol       Date:  2013-11-26       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.